Healthcare Industry News: joint replacement
News Release - November 11, 2016
OMNIlife science(TM), Inc. Achieves 10,000 Procedures Milestone for OMNIBotics(TM) Robotic-Assisted Total Knee ReplacementsRAYNHAM, Mass., Nov. 11, 2016 -- (Healthcare Sales & Marketing Network) -- OMNIlife science, Inc. ("OMNI™"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announces that surgeons have completed more than 10,000 total knee replacements worldwide using the OMNIBotics robotic-assisted total knee replacement technology platform. The OMNBotics system enables optimized implant placement using robotics driven by OMNI's proprietary ART™ software. Surgeons can efficiently plan a procedure that is specific to each patient using patented intra-operative 3-D modeling technique that eliminates the need for preoperative CT scans or x-rays and then execute the procedure using the system's patented robotic cutting guide technology.
The OMNIBotics system is modular and portable with a compact physical footprint, unlike most competitive systems, enabling it to be seamlessly incorporated into a crowded OR. The OMNI ART software is designed for flexibility and customization to any surgeon's particular approach to total knee replacement, facilitating a reduced learning curve. The software allows for intraoperative adjustments to be made easily, which can contribute to increased operative efficiency and time- savings, as well as the precise alignment of the implant that many surgeons believe can lead to more rapid recovery and a more natural feeling total knee replacement.
"As an early adopter of the OMNIBotics™ system, I am not at all surprised by the fact that a growing number of orthopaedic surgeons are embracing this technology," said Tod Northrup, D.O., orthopaedic surgeon at Flagler Hospital in St. Augustine, FL. "The results achieved with OMNIBotics in my practice have been consistently excellent for both my patients as well as for the healthcare system. It enables me to perform a truly patient-specific procedure with unparalleled accuracy, providing faster post-operative recovery time and a high level of patient satisfaction in a cost- effective manner."
OMNI expects the demand for robotic precision in the total knee replacement market to increase dramatically and so is dedicated to designing novel complementary technologies and high- performance implants, making it more cost-effective for healthcare providers to offer to their patients. OMNI's unique pay-per-procedure model is anticipated to drive easier adoption of the proven robotic-assisted total knee replacement, eliminating the need for a significant capital investment by the hospital.
"When OMNI's proven APEX Knee™ implant is precisely implanted and aligned by the surgeon with the aid of OMNIBotics technology, the result is a total knee replacement that benefits both the patient and our healthcare system," said Rick Randall, CEO. "Recent market research estimates that in the next five years, more than 20% of total knee replacement procedures will be performed using robotic assistance. The more than 10,000 successful OMNIBotics total knee procedures thus far are an excellent validation that OMNI continues to lead the way in Robotic- Assisted Total Knee Replacement surgery."
OMNI is a privately held company with a proprietary robotic platform, OMNIBotics™, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and improve patient care. For more information about OMNI, please visit www.omnils.com.
Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms "plans," "believes" or similar expressions are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.
Source: OMNIlife science
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.